Diabetes and cancer-An AACE/ACE consensus statement

Yehuda Handelsman, Derek Leroith, Zachary Bloomgarden, Samuel Dagogo-Jack, Daniel Einhorn, Alan Garber, George Grunberger, R. Harrell, Robert Gagel, Harold Lebovitz, Janet McGill, Charles Hennekens

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Epidemiologic data have demonstrated significant increases of various cancers in people with obesity and diabetes. Recently, concern has emerged that antihyperglycemic medications may also be associated with an increased prevalence of multiple cancers; however, available data are limited and conflicting. The American Association of Clinical Endocrinologists (AACE) convened a conference to review factors associated with cancer development in people with obesity and diabetes and to discuss the possible cancer risk of antihyperglycemic medications. Increased body mass index is associated with an increased risk of multiple cancers based on observational epidemiological data, and is closely associated with increased levels of endogenous insulin, insulin-like growth factors, inflammatory cytokines, and other factors that can have downstream pro-cancer growth effects. The role of hyperglycemia in cancer development is less clear, but an association cannot be ruled out, as current observational data additionally suggest an increased cancer risk in people with diabees. There is currently insufficient evidence that antihyperglycemic medications may be definitively associated with an increased cancer risk owing to a lack of data from large-scale randomized study designs. Similarly, there is also insufficient evidence showing a positive impact of these medications on cancer development. Clinicians can continue to confidently prescribe all FDA-approved antihyperglycemic medications for the management of hyperglycemia according to established practice guidelines. In patients who have an elevated cancer risk or positive family history of cancer, the cautious selection of antihyperglycemic medications is both prudent and warranted. The AACE additionally advocates for the improved treatment and management of obesity, early cancer screening in patients at increased risk, increased research collaboration, and improved study designs to address outstanding concerns surrounding the diabetes-cancer relationship.

Original languageEnglish (US)
Pages (from-to)676-693
Number of pages18
JournalEndocrine Practice
Volume19
Issue number4
DOIs
StatePublished - Jul 1 2013

Fingerprint

Consensus
Neoplasms
Hypoglycemic Agents
Obesity
Hyperglycemia
Endocrinologists
Somatomedins
Early Detection of Cancer
Practice Guidelines
Body Mass Index
Insulin
Cytokines
Growth

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Handelsman, Y., Leroith, D., Bloomgarden, Z., Dagogo-Jack, S., Einhorn, D., Garber, A., ... Hennekens, C. (2013). Diabetes and cancer-An AACE/ACE consensus statement. Endocrine Practice, 19(4), 676-693. https://doi.org/10.4158/EP13248.CS

Diabetes and cancer-An AACE/ACE consensus statement. / Handelsman, Yehuda; Leroith, Derek; Bloomgarden, Zachary; Dagogo-Jack, Samuel; Einhorn, Daniel; Garber, Alan; Grunberger, George; Harrell, R.; Gagel, Robert; Lebovitz, Harold; McGill, Janet; Hennekens, Charles.

In: Endocrine Practice, Vol. 19, No. 4, 01.07.2013, p. 676-693.

Research output: Contribution to journalArticle

Handelsman, Y, Leroith, D, Bloomgarden, Z, Dagogo-Jack, S, Einhorn, D, Garber, A, Grunberger, G, Harrell, R, Gagel, R, Lebovitz, H, McGill, J & Hennekens, C 2013, 'Diabetes and cancer-An AACE/ACE consensus statement', Endocrine Practice, vol. 19, no. 4, pp. 676-693. https://doi.org/10.4158/EP13248.CS
Handelsman Y, Leroith D, Bloomgarden Z, Dagogo-Jack S, Einhorn D, Garber A et al. Diabetes and cancer-An AACE/ACE consensus statement. Endocrine Practice. 2013 Jul 1;19(4):676-693. https://doi.org/10.4158/EP13248.CS
Handelsman, Yehuda ; Leroith, Derek ; Bloomgarden, Zachary ; Dagogo-Jack, Samuel ; Einhorn, Daniel ; Garber, Alan ; Grunberger, George ; Harrell, R. ; Gagel, Robert ; Lebovitz, Harold ; McGill, Janet ; Hennekens, Charles. / Diabetes and cancer-An AACE/ACE consensus statement. In: Endocrine Practice. 2013 ; Vol. 19, No. 4. pp. 676-693.
@article{4debfe9893ae41b3b100815dfcd4cdc3,
title = "Diabetes and cancer-An AACE/ACE consensus statement",
abstract = "Epidemiologic data have demonstrated significant increases of various cancers in people with obesity and diabetes. Recently, concern has emerged that antihyperglycemic medications may also be associated with an increased prevalence of multiple cancers; however, available data are limited and conflicting. The American Association of Clinical Endocrinologists (AACE) convened a conference to review factors associated with cancer development in people with obesity and diabetes and to discuss the possible cancer risk of antihyperglycemic medications. Increased body mass index is associated with an increased risk of multiple cancers based on observational epidemiological data, and is closely associated with increased levels of endogenous insulin, insulin-like growth factors, inflammatory cytokines, and other factors that can have downstream pro-cancer growth effects. The role of hyperglycemia in cancer development is less clear, but an association cannot be ruled out, as current observational data additionally suggest an increased cancer risk in people with diabees. There is currently insufficient evidence that antihyperglycemic medications may be definitively associated with an increased cancer risk owing to a lack of data from large-scale randomized study designs. Similarly, there is also insufficient evidence showing a positive impact of these medications on cancer development. Clinicians can continue to confidently prescribe all FDA-approved antihyperglycemic medications for the management of hyperglycemia according to established practice guidelines. In patients who have an elevated cancer risk or positive family history of cancer, the cautious selection of antihyperglycemic medications is both prudent and warranted. The AACE additionally advocates for the improved treatment and management of obesity, early cancer screening in patients at increased risk, increased research collaboration, and improved study designs to address outstanding concerns surrounding the diabetes-cancer relationship.",
author = "Yehuda Handelsman and Derek Leroith and Zachary Bloomgarden and Samuel Dagogo-Jack and Daniel Einhorn and Alan Garber and George Grunberger and R. Harrell and Robert Gagel and Harold Lebovitz and Janet McGill and Charles Hennekens",
year = "2013",
month = "7",
day = "1",
doi = "10.4158/EP13248.CS",
language = "English (US)",
volume = "19",
pages = "676--693",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "4",

}

TY - JOUR

T1 - Diabetes and cancer-An AACE/ACE consensus statement

AU - Handelsman, Yehuda

AU - Leroith, Derek

AU - Bloomgarden, Zachary

AU - Dagogo-Jack, Samuel

AU - Einhorn, Daniel

AU - Garber, Alan

AU - Grunberger, George

AU - Harrell, R.

AU - Gagel, Robert

AU - Lebovitz, Harold

AU - McGill, Janet

AU - Hennekens, Charles

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Epidemiologic data have demonstrated significant increases of various cancers in people with obesity and diabetes. Recently, concern has emerged that antihyperglycemic medications may also be associated with an increased prevalence of multiple cancers; however, available data are limited and conflicting. The American Association of Clinical Endocrinologists (AACE) convened a conference to review factors associated with cancer development in people with obesity and diabetes and to discuss the possible cancer risk of antihyperglycemic medications. Increased body mass index is associated with an increased risk of multiple cancers based on observational epidemiological data, and is closely associated with increased levels of endogenous insulin, insulin-like growth factors, inflammatory cytokines, and other factors that can have downstream pro-cancer growth effects. The role of hyperglycemia in cancer development is less clear, but an association cannot be ruled out, as current observational data additionally suggest an increased cancer risk in people with diabees. There is currently insufficient evidence that antihyperglycemic medications may be definitively associated with an increased cancer risk owing to a lack of data from large-scale randomized study designs. Similarly, there is also insufficient evidence showing a positive impact of these medications on cancer development. Clinicians can continue to confidently prescribe all FDA-approved antihyperglycemic medications for the management of hyperglycemia according to established practice guidelines. In patients who have an elevated cancer risk or positive family history of cancer, the cautious selection of antihyperglycemic medications is both prudent and warranted. The AACE additionally advocates for the improved treatment and management of obesity, early cancer screening in patients at increased risk, increased research collaboration, and improved study designs to address outstanding concerns surrounding the diabetes-cancer relationship.

AB - Epidemiologic data have demonstrated significant increases of various cancers in people with obesity and diabetes. Recently, concern has emerged that antihyperglycemic medications may also be associated with an increased prevalence of multiple cancers; however, available data are limited and conflicting. The American Association of Clinical Endocrinologists (AACE) convened a conference to review factors associated with cancer development in people with obesity and diabetes and to discuss the possible cancer risk of antihyperglycemic medications. Increased body mass index is associated with an increased risk of multiple cancers based on observational epidemiological data, and is closely associated with increased levels of endogenous insulin, insulin-like growth factors, inflammatory cytokines, and other factors that can have downstream pro-cancer growth effects. The role of hyperglycemia in cancer development is less clear, but an association cannot be ruled out, as current observational data additionally suggest an increased cancer risk in people with diabees. There is currently insufficient evidence that antihyperglycemic medications may be definitively associated with an increased cancer risk owing to a lack of data from large-scale randomized study designs. Similarly, there is also insufficient evidence showing a positive impact of these medications on cancer development. Clinicians can continue to confidently prescribe all FDA-approved antihyperglycemic medications for the management of hyperglycemia according to established practice guidelines. In patients who have an elevated cancer risk or positive family history of cancer, the cautious selection of antihyperglycemic medications is both prudent and warranted. The AACE additionally advocates for the improved treatment and management of obesity, early cancer screening in patients at increased risk, increased research collaboration, and improved study designs to address outstanding concerns surrounding the diabetes-cancer relationship.

UR - http://www.scopus.com/inward/record.url?scp=84883399648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883399648&partnerID=8YFLogxK

U2 - 10.4158/EP13248.CS

DO - 10.4158/EP13248.CS

M3 - Article

VL - 19

SP - 676

EP - 693

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 4

ER -